Elite in Lymphangioleiomyomatosis

Sergio A. Harari

Milan, IT 
Elite in Lymphangioleiomyomatosis
Milan, IT 
OverviewLocationsClinical Research

Overview

Sergio Harari practices in Milan, Italy. Mr. Harari is rated as an Elite expert by MediFind in the treatment of Lymphangioleiomyomatosis. His top areas of expertise are Lymphangioleiomyomatosis, Acute Interstitial Pneumonia, Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, and Lung Transplant.

His clinical research consists of co-authoring 187 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 25 articles and participated in 1 clinical trial in the study of Lymphangioleiomyomatosis.

Gender
Male

Locations

Milan, Italy
Other Locations
Cura, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
Enrollment Status: Completed
Publish Date: October 15, 2025
Intervention Type: Biological, Drug, Device
Study Drugs: Depemokimab, Mepolizumab, Benralizumab
Study Phase: Phase 3
Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Enrollment Status: Terminated
Publish Date: August 12, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
A Pilot Study of Nintedanib for LymphAngioleioMyomatosis (LAM)
A Pilot Study of Nintedanib for LymphAngioleioMyomatosis (LAM)
Enrollment Status: Completed
Publish Date: September 28, 2022
Intervention Type: Drug
Study Drug: Nintedanib
Study Phase: Phase 2
View 2 Less Clinical Trials

187 Total Publications

Rare pulmonary diseases and pulmonary hypertension.
Rare pulmonary diseases and pulmonary hypertension.
Journal: Current opinion in pulmonary medicine
Published: June 27, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Harari's expertise for a condition
ConditionClose
View All 10 Advanced Conditions
View All 29 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile